Can Zynerba Pharmaceuticals Inc. (ZYNE) Remain Competitive?

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE) went down by -4.07% from its latest closing price compared to the recent 1-year high of $9.00. The company’s stock price has collected 2.05% of gains in the last five trading sessions. Press Release reported 16 hours ago that Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Is It Worth Investing in Zynerba Pharmaceuticals Inc. (NASDAQ :ZYNE) Right Now?

Plus, the 36-month beta value for ZYNE is at 2.60. Opinions of the stock are interesting as 4 analysts out of 6 who provided ratings for Zynerba Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”


The 2021 Backdoor Crypto Portfolio (free)

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.

Sponsored



The average price from analysts is $6.95, which is $2.81 above the current price. ZYNE currently public float of 28.60M and currently shorts hold a 11.49% ratio of that float. Today, the average trading volume of ZYNE was 5.57M shares.

ZYNE’s Market Performance

ZYNE stocks went up by 2.05% for the week, with a monthly jump of 7.95% and a quarterly performance of 34.74%, while its annual performance rate touched 35.35%. The volatility ratio for the week stands at 5.59% while the volatility levels for the past 30 days are set at 10.04% for Zynerba Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -7.90% for ZYNE stocks with a simple moving average of 9.55% for the last 200 days.

Analysts’ Opinion of ZYNE

Many brokerage firms have already submitted their reports for ZYNE stocks, with H.C. Wainwright repeating the rating for ZYNE by listing it as a “Buy.” The predicted price for ZYNE in the upcoming period, according to H.C. Wainwright is $9 based on the research report published on December 21st of the previous year 2020.

ROTH Capital gave a rating of “Buy” to ZYNE, setting the target price at $12 in the report published on December 31st of the previous year.

ZYNE Trading at -6.79% from the 50-Day Moving Average

After a stumble in the market that brought ZYNE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.22% of loss for the given period.

Volatility was left at 10.04%, however, over the last 30 days, the volatility rate increased by 5.59%, as shares surge +8.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.14% upper at present.

During the last 5 trading sessions, ZYNE rose by +2.05%, which changed the moving average for the period of 200-days by -30.33% in comparison to the 20-day moving average, which settled at $4.88. In addition, Zynerba Pharmaceuticals Inc. saw 35.76% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for ZYNE

The total capital return value is set at -76.45, while invested capital returns managed to touch -75.58. Equity return is now at value -76.80, with -65.10 for asset returns.

Based on Zynerba Pharmaceuticals Inc. (ZYNE), the company’s capital structure generated 0.18 points at debt to equity in total, while total debt to capital is 0.18.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

The liquidity ratio also appears to be rather interesting for investors as it stands at 5.27.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Best Morning Financial Newsletter... 100% Free

Best stocks ideas

Analysts’ Upgrades & Downgrades

Important Earnings

Insider Watchlist

We do not sell or share your information with anyone.

Get The Best Stocks To Trade Every Day!...100% Free

We do not sell or share your information with anyone.